BZW2

Across TCGA pan-cancer cohorts, BZW2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BZW2 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher BZW2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BZW2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where BZW2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.805	1.000	.003	86	view →
LUAD	DFS	Quartile	All	0.448	0.820	.001	21	view →
PDAC	OS	Median	IV	0.491	0.836	.024	8	view →
LSCC	DFS	Median	II,III,IV	0.485	1.000	.006	4	view →
HNSC	OS	Median	II,III,IV	1.000	0.954	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BZW2–CCRCC (DFS)

Open the CCRCC breakdown →